In:
Journal of the American Animal Hospital Association, American Animal Hospital Association, Vol. 56, No. 3 ( 2020-05-01), p. 146-
Abstract:
The objective of this retrospective study was to report treatment outcomes in dogs with histiocytic sarcoma (HS) that were treated with nimustine (ACNU). This study evaluated data from 11 dogs including 5 with macroscopic tumors that were treated in the primary setting and 6 that underwent aggressive local therapy while being treated in the adjuvant setting. The median ACNU starting dose was 25 mg/m2 (range, 20–30 mg/m2; 3- to 5-wk intervals, 1–8 administrations). The median overall survival in the primary and adjuvant settings was 120 days (median progression-free survival [PFS], 63 days) and 400 days (median PFS, 212 days), respectively. Neutropenia was observed in eight cases (grade 1, n = 1; grade 2, n = 2; grade 3, n = 2; grade 4, n = 3) with nadir neutrophil count at 1 wk after ACNU administration. Mild gastrointestinal toxicity (grade 1–2) was observed in three cases. ACNU was well tolerated and showed a similar outcome to that seen for lomustine, which is a drug commonly used to treat canine HS, in terms of overall survival and PFS in the current study population. Further investigations will need to be undertaken to definitively determine if ACNU is an appropriate alternative to lomustine for the treatment of HS.
Type of Medium:
Online Resource
ISSN:
0587-2871
,
1547-3317
DOI:
10.5326/JAAHA-MS-6959
Language:
English
Publisher:
American Animal Hospital Association
Publication Date:
2020
SSG:
22
